Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 7;9(1):160.
doi: 10.1038/s41531-023-00599-6.

Genetic risk variants in New Yorkers of Puerto Rican and Dominican Republic heritage with Parkinson's disease

Gabriel Miltenberger-Miltenyi  1   2   3 , Roberto A Ortega  4   5 , Aloysius Domingo  6   7   8 , Rachita Yadav  6   7   8 , Ayumi Nishiyama  6 , Deborah Raymond  4   5 , Viktoriya Katsnelson  4   5 , Nikita Urval  4   5 , Matthew Swan  4   5 , Vicki Shanker  4   5 , Joan Miravite  4   5 , Ruth H Walker  4   9 , Susan B Bressman  4   5 , Laurie J Ozelius  6 , José C Cabassa #  4 , Rachel Saunders-Pullman #  10   11
Affiliations

Genetic risk variants in New Yorkers of Puerto Rican and Dominican Republic heritage with Parkinson's disease

Gabriel Miltenberger-Miltenyi et al. NPJ Parkinsons Dis. .

Abstract

There is a paucity of genetic characterization in people with Parkinson's disease (PD) of Latino and Afro-Caribbean descent. Screening LRRK2 and GBA variants in 32 New Yorkers of Puerto Rican ethnicity with PD and in 119 non-Hispanic-non-Jewish European PD cases revealed that Puerto Rican participants were more likely to harbor the LRRK2-p.G2019S variant (15.6% vs. 4.2%, respectively). Additionally, whole exome sequencing of twelve Puerto Rican and Dominican PD participants was performed as an exploratory study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Cook Shukla, L., et al. Parkinson Disease Overview. 2004 May 25 [Updated 2019 Jul 25]. in GeneReviews® [Internet] (eds Adam, M. P., Ardinger, H. H., Pagon, R. A., et al.) (University of Washington, 1993–2021).
    1. Ortega RA, et al. Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression. JAMA Netw. Open. 2021;4:e215845. doi: 10.1001/jamanetworkopen.2021.5845. - DOI - PMC - PubMed
    1. Nishioka K, et al. Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa. Neurosci. Lett. 2010;477:57–60. doi: 10.1016/j.neulet.2009.11.066. - DOI - PMC - PubMed
    1. Ruiz-Martínez J, et al. Penetrance in Parkinson’s disease related to the LRRK2 R1441G mutation in the Basque Country (Spain) Mov. Disord. 2010;25:2340–2345. doi: 10.1002/mds.23278. - DOI - PubMed
    1. Cruz-Vicente P, Passarinha LA, Silvestre S, Gallardo E. Recent developments in new therapeutic agents against Alzheimer and Parkinson diseases: in-silico approaches. Molecules. 2021;26:2193. doi: 10.3390/molecules26082193. - DOI - PMC - PubMed

LinkOut - more resources